Related posts

Earnings mixed, Powell holds ratesFeds hold rates, markets partially reboundBitcoin and gold flirt with highs, stocks fade
Investor Insights

This summary was created by AI, based on 45 opinions in the last 12 months.

Pfizer Inc has seen a mixed bag of reviews from experts. Some see it as a value trap with little growth and tough industry conditions, while others view it as a strong long-term investment with a solid dividend yield and potential for growth from new drugs and acquisitions. The stock has been impacted by the transition away from Covid-related sales, patent cliffs, and disappointing drug trials, but some experts believe it is close to bottoming and offers good value for investors. Overall, the company is seen as having potential for growth but also facing challenges, making it a somewhat divisive stock among experts.

Consensus
Mixed
Valuation
Fair Value
BUY
Pfizer Inc

Great company, that has turned the corner. Solid dividend with lots of cash on the balance sheet. 

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

It hasn't done much since the 1990's except during Covid. It's surprising that it is hiring a chief strategy and innovation officer that has been down on the stock for a decade, except for the oncology component.

biotechnology / pharmaceutical
BUY
Pfizer Inc

Believes stock is bottoming out right now. New products are going to present opportunity. ~5.5% also good. 

biotechnology / pharmaceutical
BUY
Pfizer Inc
They reported beats and raised forecast

They pay over a 6% dividend and trades at 9x PE. A wonderful story here. Will grow at a realistic 3-8% as you collect that dividend.

biotechnology / pharmaceutical
TOP PICK
Pfizer Inc

It is down 60% from its peak and trading at 10X forward earnings with a 6% dividend yield, It took the windfall cash from the Covid vaccines, etc. and re-invested in new growth areas such as cancer, diabetic and weight loss treatments/ drugs., It is out of favour and there is potential for growth.
Buy 11  Hold 15  Sell 0

(Analysts’ price target is $31.76)
biotechnology / pharmaceutical
COMMENT
Pfizer Inc

It reports Wednesday. He wants to hear how their purchase of Seagan has impacted the numbers.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

No, though it might bounce and you can collect their dividend.

biotechnology / pharmaceutical
HOLD
Pfizer Inc

Industry, overall, is fairly mature. Challenging to get drugs approved. Pharma companies are struggling to grow, dealing with patent cliffs. Flipside is generating good cashflows. Very attractive for income, but don't own it for share price performance, since growth is challenged. Yield is 6.5%, safe.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc
What is a CDR?

A CDR lets you bypass any U.S. estate probate tax issues. He owned Pfizer during Covid. Shares have slid since then, below its 200-day moving average. Could be some value at 12x forward PE, but won't touch it.

biotechnology / pharmaceutical
TOP PICK
Pfizer Inc

A very contrarian pick. Why now? Company's pivoting from Covid to cancer. Unfortunately, cancer is a huge market with 1 in 3 being diagnosed. Very strong lineup of potential new blockbuster drugs, management confidence is high on them. Market underappreciates it. Estimated to grow earnings 14%. Trades at 10x, with nice yield of 5.96%.

Near the bottom, won't go much lower. Not if it will work, but when. You get a nice dividend. Tomorrow's winner.

(Analysts’ price target is $32.26)
biotechnology / pharmaceutical
WATCH
Pfizer Inc

Starting to look at it. Just made an acquisition. Growth rates starting to accelerate.

biotechnology / pharmaceutical
BUY
Pfizer Inc

Currently - stock is at a low price which presents a good buying opportunity. Excellent R&D department. Lots of products coming to the market. Dividend is able to help returns too. Obesity drugs also adding to bottom line (trendy product). 

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Hurting. He considers it in a downtrend, lower highs and lower lows, until proven otherwise. Proof that it's over is you start to see consolidation, little zig-zags on the chart. Could start soon, but hasn't yet.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Great company, Covid saviour. Ran up on that, now falling off. Back to more normalized levels. Not his first choice. He owns MRK.

biotechnology / pharmaceutical
BUY
Pfizer Inc

Would recommend buying even with share price weakness. Does not believe market is pricing fairly. Dividend is safe. 

biotechnology / pharmaceutical
Showing 1 to 15 of 818 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 18

Total Signals / Votes : 35

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 35 stock analysts published opinions about PFE-N. 13 analysts recommended to BUY the stock. 18 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

35 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2024-05-23, Pfizer Inc (PFE-N) stock closed at a price of $28.69.